SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GLAXO (GLX) -- Ignore unavailable to you. Want to Upgrade?


To: tide who wrote (185)7/8/1998 9:13:00 PM
From: Jeff Litwin  Read Replies (2) | Respond to of 222
 
Wake up everybody!! There will be an article in tomorrow's New England Journal of Medicine showing that GLX's Lamivudine was highly effective in suppressing the adverse effects of Hepatitis B. It recommends Lamivudine as the drug of choice. Hepatitis B is a major problem in Asia and this can be a major market for this product. Hoping that the news media picks this up and that there will be a pop in the price tomorrow.